Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

PFS Clinical Trial

Official title:
A Prospective, Single Arm, Single Center, Phase II Clinical Trial of Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

Status Recruiting

Clinical Trial Summary

A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04520035
Study type	Interventional
Source	Fudan University
Contact	wang jia lei, doctor
Phone	18017312369
Email	haitunqiao@hotmail.com
Status	Recruiting
Phase	Phase 2
Start date	August 1, 2020
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04425187` - Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC	Phase 2
Not yet recruiting	`NCT05638984` - Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05267366` - Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC	Phase 2
Recruiting	`NCT05267288` - Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02629718` - Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer	Phase 3